Cedra names two new directors

They join business development in generics and automation for the bioanalytical division

Cedra Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, has appointed John Pottier as senior director of business development in generics and Thomas Lloyd as director of automation for the Bioanalytical Group.

Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.

Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.

Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.

You may also like

Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Ingredients

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples
Research & Development

EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health

The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications
Research & Development

Biohm Technologies expands R&D footprint with new microbiome lab in Atlanta

The company has opened a state-of-the-art research lab at Portal Innovations’ Science Square campus in Atlanta, strengthening its microbiome R&D capabilities
Research & Development

Certain medicines accelerate elimination of PFAS from the body, Gothenburg study shows

Researchers at the University of Gothenburg have found that two cholesterol-lowering drugs, cholestyramine and colesevelam, can significantly speed up the removal of harmful PFAS chemicals from the body
Research & Development

Bioengineered bone marrow model successfully used in cancer research

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model in vital leukaemia research
Subscribe now